Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Amarin Cuts Half of Staff After Negative FDA Panel

By Drug Discovery Trends Editor | October 22, 2013

Specialty drugmaker Amarin Corp. is eliminating half of its employees in the wake of an overwhelmingly negative Food and Drug Administration meeting that has put the future of the company’s lead product in jeopardy.
The company did not say how many employees would be affected. At the end of 2012 the company reported 111 full-time employees, according to a regulatory filing.
Last week a panel of outside advisers voted 9-2 against recommending broader use of Vascepa, which is designed to lower triglycerides, a type of fat in the bloodstream. The FDA is not required to follow the group’s advice, though it often does. Analysts had predicted a positive vote from the group.
Amarin said in a statement that it is continuing discussions with the FDA, but the terminations suggest the company does not expect approval anytime soon.
“Given the outcome of the advisory committee meeting, Amarin feels this shift in staffing is the appropriate corporate action,” the company said in a release.
At the end of September, Amarin had about $226 million in cash and cash equivalents. The company said it expects about $3 million in restructuring expenses in association with the layoffs.
Vascepa was approved in 2012 for a relatively narrow use in patients with unusually high triglyceride levels. Dublin-based Amarin has asked the FDA to allow marketing of the drug for patients with high triglyceride levels and heart disease who are already taking a statin drug to help control their cholesterol.
A majority of panelists said that while Vascepa significantly lowers fat levels, it is unclear whether that actually translates into fewer heart attacks. The panel members said the FDA should delay a decision on expanding the drug’s use until Amarin completes a study of heart attack rates in patients. Results from that study are not expected until 2015 or 2016.
Vascepa is a prescription-strength form of an omega-3 fatty acid found in fish oil.
Amarin said it plans to keep half of its best-performing salespeople on the job.
Date: October 22, 2013
Source: Associated Press

Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE